Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 11 | 2024 | 314 | 3.820 |
Why?
|
| Onychomycosis | 6 | 2016 | 8 | 2.930 |
Why?
|
| Skin Neoplasms | 15 | 2025 | 897 | 2.880 |
Why?
|
| Foot Dermatoses | 4 | 2016 | 7 | 1.980 |
Why?
|
| Public Health | 3 | 2024 | 280 | 1.840 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2024 | 95 | 1.640 |
Why?
|
| Melanoma | 7 | 2025 | 954 | 1.500 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2019 | 69 | 1.250 |
Why?
|
| Keratosis, Actinic | 4 | 2020 | 14 | 1.190 |
Why?
|
| Skin Diseases | 2 | 2023 | 136 | 1.020 |
Why?
|
| Tinea | 2 | 2016 | 6 | 0.980 |
Why?
|
| Dermatology | 2 | 2022 | 30 | 0.980 |
Why?
|
| Candidiasis, Oral | 1 | 2024 | 2 | 0.910 |
Why?
|
| Vulvar Neoplasms | 1 | 2025 | 22 | 0.910 |
Why?
|
| Mycobacterium avium Complex | 1 | 2024 | 20 | 0.910 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2024 | 24 | 0.900 |
Why?
|
| Felty Syndrome | 1 | 2023 | 2 | 0.850 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2024 | 138 | 0.850 |
Why?
|
| Hand Dermatoses | 1 | 2023 | 10 | 0.840 |
Why?
|
| Sweet Syndrome | 1 | 2023 | 10 | 0.840 |
Why?
|
| Dermatitis | 1 | 2023 | 28 | 0.840 |
Why?
|
| Crows | 1 | 2022 | 1 | 0.770 |
Why?
|
| Fungemia | 1 | 2022 | 23 | 0.760 |
Why?
|
| Skin Lightening Preparations | 1 | 2022 | 1 | 0.760 |
Why?
|
| Administration, Cutaneous | 8 | 2020 | 67 | 0.750 |
Why?
|
| Invasive Fungal Infections | 1 | 2022 | 19 | 0.750 |
Why?
|
| Neutropenia | 1 | 2023 | 205 | 0.740 |
Why?
|
| Impetigo | 2 | 2018 | 5 | 0.730 |
Why?
|
| Quinolones | 2 | 2018 | 58 | 0.710 |
Why?
|
| Muscle Neoplasms | 1 | 2021 | 21 | 0.710 |
Why?
|
| Lipoma | 1 | 2021 | 26 | 0.710 |
Why?
|
| Aminopyridines | 2 | 2018 | 55 | 0.700 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 414 | 0.690 |
Why?
|
| Doxycycline | 2 | 2020 | 121 | 0.680 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 140 | 0.680 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 131 | 0.660 |
Why?
|
| Travel-Related Illness | 1 | 2020 | 6 | 0.660 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2020 | 5 | 0.650 |
Why?
|
| Rickettsia Infections | 1 | 2020 | 7 | 0.650 |
Why?
|
| Rickettsia | 1 | 2020 | 14 | 0.650 |
Why?
|
| Diterpenes | 1 | 2020 | 29 | 0.640 |
Why?
|
| Masks | 1 | 2020 | 40 | 0.640 |
Why?
|
| Dermatomycoses | 4 | 2024 | 18 | 0.640 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 127 | 0.630 |
Why?
|
| Refusal to Treat | 1 | 2019 | 9 | 0.630 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 30 | 0.630 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 1 | 0.620 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 85 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 2553 | 0.620 |
Why?
|
| Erythema | 1 | 2019 | 29 | 0.610 |
Why?
|
| Nail Biting | 1 | 2019 | 4 | 0.610 |
Why?
|
| Humans | 51 | 2025 | 132256 | 0.600 |
Why?
|
| Treatment Refusal | 1 | 2019 | 80 | 0.600 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 58 | 0.590 |
Why?
|
| Trichotillomania | 1 | 2019 | 34 | 0.590 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 81 | 0.590 |
Why?
|
| Standard of Care | 1 | 2019 | 134 | 0.580 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1161 | 0.580 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 74 | 0.570 |
Why?
|
| Acetylcysteine | 1 | 2019 | 82 | 0.570 |
Why?
|
| Triazoles | 5 | 2016 | 147 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1304 | 0.560 |
Why?
|
| Cheek | 1 | 2017 | 25 | 0.520 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 21 | 0.520 |
Why?
|
| Rosacea | 2 | 2024 | 13 | 0.510 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 49 | 0.510 |
Why?
|
| Informed Consent | 1 | 2019 | 346 | 0.510 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1966 | 0.510 |
Why?
|
| Boron Compounds | 4 | 2016 | 34 | 0.480 |
Why?
|
| Streptococcal Infections | 1 | 2018 | 248 | 0.480 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2016 | 40 | 0.470 |
Why?
|
| Aminoquinolines | 3 | 2010 | 34 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.450 |
Why?
|
| Biopsy | 3 | 2019 | 1288 | 0.440 |
Why?
|
| United States | 9 | 2025 | 11675 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 768 | 0.410 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 569 | 0.410 |
Why?
|
| Pandemics | 1 | 2020 | 1186 | 0.380 |
Why?
|
| Neglected Diseases | 2 | 2024 | 152 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 623 | 0.350 |
Why?
|
| Consensus | 2 | 2024 | 658 | 0.340 |
Why?
|
| Pyridones | 3 | 2016 | 131 | 0.340 |
Why?
|
| Psoriasis | 2 | 2024 | 48 | 0.340 |
Why?
|
| Skin Diseases, Parasitic | 2 | 2010 | 5 | 0.340 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 25 | 0.330 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2019 | 831 | 0.320 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2010 | 23 | 0.320 |
Why?
|
| Hot Temperature | 1 | 2010 | 141 | 0.320 |
Why?
|
| Middle Aged | 13 | 2025 | 29026 | 0.320 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 10 | 0.310 |
Why?
|
| Prevalence | 3 | 2025 | 2664 | 0.300 |
Why?
|
| Azithromycin | 1 | 2008 | 43 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3358 | 0.280 |
Why?
|
| Treatment Outcome | 10 | 2024 | 13030 | 0.280 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2017 | 21 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7140 | 0.260 |
Why?
|
| Silicone Gels | 1 | 2006 | 4 | 0.260 |
Why?
|
| Aged | 10 | 2025 | 21483 | 0.260 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2006 | 7 | 0.260 |
Why?
|
| Male | 17 | 2023 | 65018 | 0.260 |
Why?
|
| Cosmetic Techniques | 1 | 2006 | 11 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 77 | 0.250 |
Why?
|
| Entamoebiasis | 1 | 2006 | 3 | 0.250 |
Why?
|
| Entamoeba histolytica | 1 | 2006 | 14 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 899 | 0.250 |
Why?
|
| Naphthalenes | 2 | 2016 | 38 | 0.240 |
Why?
|
| Delphi Technique | 2 | 2024 | 240 | 0.240 |
Why?
|
| Skin | 3 | 2021 | 527 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1829 | 0.230 |
Why?
|
| Female | 14 | 2025 | 70791 | 0.230 |
Why?
|
| Administration, Topical | 4 | 2015 | 140 | 0.230 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 13 | 0.230 |
Why?
|
| Dielectric Spectroscopy | 1 | 2024 | 3 | 0.230 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2015 | 67 | 0.220 |
Why?
|
| Condylomata Acuminata | 2 | 2018 | 15 | 0.220 |
Why?
|
| Pruritus | 1 | 2024 | 47 | 0.220 |
Why?
|
| Complementary Therapies | 1 | 2024 | 42 | 0.220 |
Why?
|
| Algorithms | 2 | 2024 | 1725 | 0.220 |
Why?
|
| Filgrastim | 1 | 2023 | 12 | 0.210 |
Why?
|
| Blister | 1 | 2023 | 22 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 666 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 761 | 0.210 |
Why?
|
| Adult | 11 | 2025 | 31620 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 803 | 0.200 |
Why?
|
| Mohs Surgery | 2 | 2024 | 38 | 0.200 |
Why?
|
| Incidence | 3 | 2025 | 3377 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1653 | 0.190 |
Why?
|
| Philippines | 1 | 2022 | 23 | 0.190 |
Why?
|
| Skin Pigmentation | 1 | 2022 | 29 | 0.190 |
Why?
|
| Drug Resistance, Fungal | 1 | 2022 | 30 | 0.190 |
Why?
|
| Recurrence | 2 | 2016 | 1453 | 0.190 |
Why?
|
| Molluscum Contagiosum | 1 | 2021 | 11 | 0.180 |
Why?
|
| Asia | 1 | 2022 | 126 | 0.180 |
Why?
|
| Candida | 1 | 2022 | 84 | 0.180 |
Why?
|
| Scapula | 1 | 2021 | 15 | 0.180 |
Why?
|
| India | 1 | 2022 | 238 | 0.180 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 47 | 0.170 |
Why?
|
| Young Adult | 5 | 2025 | 9970 | 0.170 |
Why?
|
| Zimbabwe | 1 | 2020 | 9 | 0.170 |
Why?
|
| Skin Ulcer | 1 | 2020 | 32 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 71 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 749 | 0.160 |
Why?
|
| Dermatologists | 1 | 2019 | 5 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 130 | 0.160 |
Why?
|
| Back | 1 | 2019 | 11 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 29 | 0.150 |
Why?
|
| Surgeons | 1 | 2024 | 286 | 0.150 |
Why?
|
| Human papillomavirus 11 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Human papillomavirus 6 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2020 | 131 | 0.150 |
Why?
|
| Skin Cream | 1 | 2018 | 7 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2019 | 110 | 0.140 |
Why?
|
| Neck | 1 | 2019 | 142 | 0.140 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 79 | 0.140 |
Why?
|
| Hydrogels | 1 | 2018 | 108 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 31 | 0.130 |
Why?
|
| Nevus | 1 | 2016 | 35 | 0.130 |
Why?
|
| Tinea Pedis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Europe | 2 | 2018 | 373 | 0.130 |
Why?
|
| Itraconazole | 1 | 2016 | 24 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 663 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3761 | 0.120 |
Why?
|
| Fluconazole | 1 | 2016 | 51 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 84 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 382 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 571 | 0.120 |
Why?
|
| Pharmaceutical Solutions | 1 | 2015 | 10 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 437 | 0.110 |
Why?
|
| Imidazoles | 1 | 2016 | 219 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2016 | 209 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2016 | 699 | 0.100 |
Why?
|
| Sunscreening Agents | 1 | 2013 | 4 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17396 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 26 | 0.100 |
Why?
|
| Margins of Excision | 3 | 2017 | 57 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2018 | 823 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 473 | 0.100 |
Why?
|
| Child | 6 | 2021 | 25784 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 462 | 0.100 |
Why?
|
| Australia | 1 | 2013 | 185 | 0.100 |
Why?
|
| Infant | 3 | 2018 | 13049 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 198 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 447 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 731 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 234 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2018 | 14736 | 0.090 |
Why?
|
| Porokeratosis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 743 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2010 | 30 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1610 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2020 | 3736 | 0.080 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 4 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2010 | 138 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 665 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2010 | 21 | 0.080 |
Why?
|
| Adolescent | 4 | 2018 | 20561 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 956 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1304 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 59 | 0.080 |
Why?
|
| Risk Factors | 2 | 2016 | 10946 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3853 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 185 | 0.080 |
Why?
|
| Minocycline | 1 | 2008 | 42 | 0.070 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 392 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 280 | 0.070 |
Why?
|
| Survival Rate | 1 | 2012 | 2196 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 1250 | 0.060 |
Why?
|
| Mass Screening | 1 | 2013 | 830 | 0.060 |
Why?
|
| Etanercept | 1 | 2006 | 47 | 0.060 |
Why?
|
| Transsexualism | 1 | 2006 | 15 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 126 | 0.060 |
Why?
|
| Thigh | 1 | 2006 | 51 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 82 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1254 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3414 | 0.060 |
Why?
|
| Capsaicin | 1 | 2024 | 20 | 0.060 |
Why?
|
| Animals | 2 | 2022 | 34850 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2005 | 139 | 0.060 |
Why?
|
| Penicillins | 1 | 2005 | 155 | 0.060 |
Why?
|
| Chromoblastomycosis | 1 | 2024 | 1 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 385 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 100 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 329 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 590 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 3093 | 0.050 |
Why?
|
| Tropical Medicine | 1 | 2024 | 103 | 0.050 |
Why?
|
| Cantharidin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Curettage | 1 | 2021 | 6 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 5016 | 0.040 |
Why?
|
| Global Health | 1 | 2006 | 644 | 0.040 |
Why?
|
| Dosage Forms | 2 | 2010 | 9 | 0.040 |
Why?
|
| Russia | 1 | 2018 | 37 | 0.040 |
Why?
|
| South Africa | 1 | 2018 | 108 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 3 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1883 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 134 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 470 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 306 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1671 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2161 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 1125 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 306 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 134 | 0.020 |
Why?
|
| Scalp | 1 | 2010 | 57 | 0.020 |
Why?
|
| Face | 1 | 2010 | 189 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5412 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 6452 | 0.010 |
Why?
|